Abstract: The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.

Abstract: The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.

Abstract: The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.

Abstract: An evapo-control valve, which is disposed in a pipe for connecting a fuel tank and a canister, comprises a fuel tank side connecting port which communicates with the fuel tank, a canister side connecting port which communicates with the canister, an intake manifold side connecting port which communicates with an intake manifold, a closing valve for permitting the canister side connecting port to communicate with the fuel tank side connecting port by the negative pressure in the intake manifold side connecting port during the operation of an engine, and a check valve for permitting the atmosphere in the canister to communicate with the fuel tank when the fuel tank is negatively pressurized due to cold weather during the stop of the engine.